ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.51 | 0.31 | 0.06 |
| FCF Yield | 2.75% | 0.38% | -9.56% | -63.96% |
| EV / EBITDA | 26.92 | 215.32 | -21.04 | -4.66 |
| Quality | ||||
| ROIC | 50.31% | 7.72% | -16.41% | -27.92% |
| Gross Margin | 51.48% | 34.44% | 22.89% | 1.45% |
| Cash Conversion Ratio | 0.60 | -0.31 | 0.90 | 1.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.40% | 47.21% | 53.96% | 40.24% |
| Free Cash Flow Growth | 2,782.88% | 105.20% | 41.68% | -9.72% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 17.59 | -1.71 | -0.97 |
| Interest Coverage | 9.98 | 0.86 | -2.04 | -4.47 |
| Efficiency | ||||
| Inventory Turnover | 1.22 | 0.98 | 0.73 | 0.64 |
| Cash Conversion Cycle | 307.44 | 377.83 | 497.69 | 642.69 |